Registrate
con nosotros
|
|
|
|
No:328
|
Noviembre
25, 2010 |
|
Cannabis
fumada para el dolor neurop�tico cr�nico: un ensayo controlado
aleatorizado
|
|
Smoked
cannabis for chronic neuropathic pain: a randomized controlled
trial.
Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa
A, Bennett GJ, Collet JP.
Department of Anesthesia, McGill University, Montr�al,
Que.
CMAJ.
2010 Oct 5;182(14):E694-701. Epub 2010 Aug 30.
Abstract
BACKGROUND: Chronic neuropathic pain affects 1%-2% of the adult
population and is often refractory to standard pharmacologic
treatment. Patients with chronic pain have reported using smoked
cannabis to relieve pain, improve sleep and improve mood. METHODS:
Adults with post-traumatic or postsurgical neuropathic pain were
randomly assigned to receive cannabis at four potencies (0%, 2.5%,
6% and 9.4% tetrahydrocannabinol) over four 14-day periods in a
crossover trial. Participants inhaled a single 25-mg dose through a
pipe three times daily for the first five days in each cycle,
followed by a nine-day washout period. Daily average pain intensity
was measured using an 11-point numeric rating scale. We recorded
effects on mood, sleep and quality of life, as well as adverse
events. RESULTS: We recruited 23 participants (mean age 45.4
[standard deviation 12.3] years, 12 women [52%]), of whom 21
completed the trial. The average daily pain intensity, measured on
the 11-point numeric rating scale, was lower on the prespecified
primary contrast of 9.4% v. 0% tetrahydrocannabinol (5.4 v. 6.1,
respectively; difference = 0.7, 95% confidence interval [CI]
0.02-1.4). Preparations with intermediate potency yielded
intermediate but nonsignificant degrees of relief. Participants
receiving 9.4% tetrahydrocannabinol reported improved ability to
fall asleep (easier, p = 0.001; faster, p < 0.001; more drowsy,
p = 0.003) and improved quality of sleep (less wakefulness, p =
0.01) relative to 0% tetrahydrocannabinol. We found no differences
in mood or quality of life. The most common drug-related adverse
events during the period when participants received 9.4%
tetrahydrocannabinol were headache, dry eyes, burning sensation in
areas of neuropathic pain, dizziness, numbness and cough.
CONCLUSION: A single inhalation of 25 mg of 9.4%
tetrahydrocannabinol herbal cannabis three times daily for five
days reduced the intensity of pain, improved sleep and was well
tolerated. Further long-term safety and efficacy studies are
indicated. (International Standard Randomised Controlled Trial
Register no. ISRCTN68314063).
Lea
el art�culo completo en el siguiente enlace:
http://www.cmaj.ca/cgi/reprint/182/14/E694
|
| El
sistema endocannabinoide y el dolor |
|
The
endocannabinoid system and pain.
Guindon J, Hohmann AG.
Neuroscience and Behavior Program, Department of Psychology,
University of Georgia, Athens, GA 30602-3013, USA.
CNS Neurol Disord Drug Targets. 2009
Dec;8(6):403-21.
Abstract
The therapeutic potential of cannabinoids has been the topic of
extensive investigation following the discovery of cannabinoid
receptors and their endogenous ligands. Cannabinoid receptors and
their endogenous ligands are present at supraspinal, spinal and
peripheral levels. Cannabinoids suppress behavioral responses to
noxious stimulation and suppress nociceptive processing through
activation of cannabinoid CB(1) and CB(2) receptor subtypes.
Endocannabinoids, the brain's own cannabis-like substances, share
the same molecular target as Delta(9)-tetrahydrocannabinol, the
main psychoactive component in cannabis. Endocannabinoids serve as
synaptic circuit breakers and regulate multiple physiological and
pathological conditions, e.g. regulation of food intake,
immunomodulation, inflammation, analgesia, cancer, addictive
behavior, epilepsy and others. This review will focus on uncovering
the roles of anandamide and 2-arachidonoylglycerol, the two best
characterized endocannabinoids identified to date, in controlling
nociceptive responding. The roles of anandamide and
2-arachidonoylglycerol, released under physiological conditions, in
modulating nociceptive responding at different levels of the
neuraxis will be emphasized in this review. Effects of modulation
of endocannabinoid levels through inhibition of endocannabinoid
hydrolysis and uptake is also compared with effects of exogenous
administration of synthetic endocannabinoids in acute, inflammatory
and neuropathic pain models. Finally, the therapeutic potential of
the endocannabinoid signaling system is discussed in the context of
identifying novel pharmacotherapies for the treatment of
pain.
Art��culo en
PDF
|
| Novedades
sobre las potencialidades terap�uticas del Cannabis y el sistema
cannabinoide |
|
Marta
Duran, Joan-Ramon Laporte y Dolors Capell�
Fundaci� Institut Catal� de Farmacologia. Hospitals Vall
d'Hebron.
Universitat Aut�noma de Barcelona. Barcelona. Espa�a.
Med Clin (Barc) 2004;122(10):390-8
Durante la �ltima d�cada una rica investigaci�n b�sica ha permitido
caracterizar el sistema cannabinoide. Comienzan a acumularse
pruebas de que los cannabinoides podr�an ser eficaces en el
tratamiento de las n�useas y v�mitos por quimioter�picos
antineopl�sicos, el dolor, la espasticidad y otros s�ntomas de la
esclerosis m�ltiple y algunas alteraciones del movimiento. Hay que
esperar la publicaci�n de los resultados de los ensayos cl�nicos en
curso con extractos de Cannabis por v�a oral y sublingual para
definir de manera precisa su lugar en terap�utica en estas y otras
indicaciones. Actualmente se est�n desarrollando nuevas v�as de
administraci�n como la rectal, sublingual o transd�rmica para
evitar los efectos perjudiciales del humo del
Cannabis fumado. Aunque el futuro inmediato parece basarse en
medicamentos derivados directamente del Cannabis, la investigaci�n
actual tiende a desarrollar por un lado nuevos f�rmacos que act�en
potenciando o inhibiendo los efectos de los cannabinoides end�genos
y
por otro, f�rmacos sint�ticos agonistas y antagonistas de los
receptores cannabinoides.
Palabras clave: Sistema cannabinoide. Cannabis. Cannabinoides.
Dolor. Espasticidad. N�useas y v�mitos. Eficacia. Efectos
indeseados.
Art�culo en
PDF
|
|
|
Anestesiolog�a
y Medicina del Dolor
|
|
|